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Inflammation is a host protective response to noxious stimuli, and 
excessive production of pro-inflammatory mediators by macrophages (mφ) can 
lead to numerous pathological conditions. In this study, immunomodulatory 
effects of immobilized and soluble glycosaminoglycans (GAGs) on mouse bone 
marrow-derived mφ were compared by measuring nitric oxide (NO). We 
demonstrate here that all GAGs studied except for heparin were able to 
modulate interferon-/lipopolysaccharide (IFN-/LPS)-induced NO release by 
mφ to varying extents after 24 h of incubation. In particular, the modulatory 
activities of soluble chondroitin-6-sulfate (C6S), hyaluronic acid and heparan 
sulfate altered markedly after covalent immobilization. Among them, soluble 
C6S exhibited the strongest NO inhibitory activity, and the inhibition was dose- 
and time-dependent. Moreover, C6S significantly reduced pro-inflammatory 
cytokines interleukin (IL)-6 and tumor necrosis factor (TNF)- production by 
IFN-/LPS- or LPS-activated mφ. Specifically, the C6S-mediated suppression of 
mφ pro-inflammatory phenotype was accompanied by an increase in the IL-10 
level, suggesting a possible switch towards anti-inflammatory/wound healing M2 
state. In addition, the highest magnitude of inhibitory effects was obtained when 
cells were pre-treated with C6S prior to IFN-/LPS or LPS challenge, suggesting 
an additional role for C6S in protection against microbial infection. Further 
investigations reveal that the anti-inflammatory effects of C6S on activated mφ 






Inflammation is a host protective response to noxious stimuli, such as 
tissue injury, chemical irritants and infection. It is a finely orchestrated process 
involves (a) release of chemicals by the injured tissue; (b) recruitment of 
leukocytes that secrete a multitude of pro-inflammatory mediators to remove 
damaged tissue or pathogens; and (c) resolution of inflammatory responses [1, 
2]. Although inflammation set the stage for the subsequent healing process, 
excessive production of pro-inflammatory mediators can greatly hinder the 
process, leading to pathological conditions such as psoriasis, septic shock and 
autoimmune diseases [3, 4]. 
Macrophages (mφ), a pivotal component of the innate immune system, are 
considered as the key player of inflammatory responses [2]. In vitro, mφ are 
typically activated to pro-inflammatory phenotype (a.k.a. M1 mφ) by exposure to 
a priming signal IFN- along with microbial entities such as lipopolysaccharide 
(LPS) [5]. Recognition of LPS by mφ occurs largely via its engagement with 
Toll-like receptor 4-myeloid differentiation protein–2 (TLR4/MD2) complex found 
on the cell membrane. This subsequently triggers intracellular signal 
transduction, eventually leading to the release and translocation of transcription 
factor NF-B (p65 and p50) subunits from cytosol to the nucleus where it 
promotes the synthesis of pro-inflammatory cytokines TNF-, IL-6, IL-1β and IL-
12 etc [5-7]. In the murine system, these cells can also be easily identified by 
their production of nitric oxide (NO) catalyzed by inducible NO synthase (iNOS) 
[5, 8].   
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On the other hand, in vitro exposure of mφ to certain cytokines, such as 
IL-4 and IL-13, resulted in anti-inflammatory/wound healing subsets (a.k.a. M2 
mφ) [5, 9, 10]. Such M2 mφ express relatively lower amount of pro-inflammatory 
mediators, but higher levels of anti-inflammatory mediators, such as cytokine IL-
10 and arginase activity [8-10]. Recent data indicates that the activated mφ are 
still able to switch their functional phenotypes in response to 
microenvironmental cues rather than exhibit a stable, distinct phenotype [11]. 
As such, biomolecules that are able to attenuate mφ inflammatory responses 
and modulate its phenotypic shift toward the M2 state would be of interest for 
the design of next-generation therapeutic modalities. 
GAGs are linear, heterogeneous polysaccharides that ubiquitously 
expressed on the cell membrane, as ECM components or as soluble molecules 
in the body [12]. Among the myriad of cellular activities regulated by these 
molecules, certain GAGs such as heparan sulfate (HS) and hyaluronic acid 
(HA) have been shown to coordinate leukocyte recruitment and activation, as 
well as inflammatory mediator production at the inflamed site [13-15]. Because 
of their diverse biological activities and therapeutic potential, GAGs have been 
extensively investigated for tissue engineering applications [16-18]. 
Chondroitin sulfate (CS) is a major member of the GAG family that 
predominantly found in cartilage, bone, skin and blood vessels [12]. It consist of 
repeating disaccharide units of D-glucuronic acid (GlcA) and N-acetyl-D-
galactosamine (GalNAc) that is usually sulfated at either C-4 (chondroitin-4-
sulfate, C4S) or C-6 (chondroitin-6-sulfate, C6S) of GalNAc [12, 19]. The 
immunomodulatory properties of CS are best demonstrated by its therapeutic 
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benefits in the treatment of osteoarthritis [20, 21]. In vitro, CS (mainly C4S and 
C6S) effectively reduces the generation of pro-inflammatory cytokines, reactive 
oxygen species and NO by chondrocytes and synovial cells [22, 23]. 
Accordingly, CS may exert its anti-inflammatory effects by diminishing the 
expression of p38MAPK phosphorylation and NF-B activation in these cells. 
On the other hand, CS from whale cartilage induced the release of NO, but not 
of pro-inflammatory cytokines (IL-6, IL-1, IL-12, prostaglandin E2 and IFN-), 
by resident mouse peritoneal mφ [24]. 
Conventionally, the biological activities of GAGs were studied with the 
molecule in solution [24, 25]. GAGs have also been surface-immobilized or 
used as scaffold materials for tissue engineering [17, 18, 26, 27]. Studies have 
shown that immobilization can greatly alter the bioactivity of some GAGs. For 
example, IFN- bound to immobilized-GAGs is biologically active while its 
activity is inhibited by soluble GAGs [28]. C6S, which is normally devoid of anti-
coagulant activities, inhibits thrombin generation when coated on glass surfaces 
[29]. In another study, cross-linked C6S was reported to be a more potent 
chondrogenic stimulus for human mesenchymal stem cells than soluble C6S 
[26]. Despite these findings, the effects of GAG immobilization on its 
immunomodulatory activity are still poorly documented.  
Based on these observations, this study was designed to explore the anti-
inflammatory properties of GAGs using mouse bone marrow-derived mφ. To 
achieve this goal, we first compared the inhibitory effects of major GAGs, 
presented as either immobilized or soluble molecules, on IFN-/LPS-induced 
NO production by mφ. Given the fact that GAGs exist naturally in both these 
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forms, we hypothesize that mode of GAG presentation may influence their 
immunomodulatory properties. In the second part of the study, the anti-
inflammatory actions of soluble C6S, the most potent of all GAGs tested, were 
further elucidated by evaluating the dose- and time dependency of the 
responses along with the production of major pro- and anti-inflammatory 
cytokines by mφ. In addition, we sought to identify the mechanism responsible 
for the anti-inflammatory actions of C6S. 
 
2. Materials and Methods 
2.1 Reagents and antibodies 
GAGs used in this study includes C6S from shark cartilage, C4S from 
bovine trachea, HS from bovine kidney (all were purchased from Sigma-Aldrich, 
Japan), HA (200 kDa; DENKA Co. Ltd., Japan) and heparin (Hp) (Fuso 
Pharmaceutical Industries Ltd., Japan). GAG solutions were prepared freshly in 
MilliQ water at indicated concentrations and filtered through a 0.02 µm syringe 
filter (Millipore Corp., Japan). The prepared GAG solutions were endotoxin-free, 
as verified by the Limulus amoebocyte lysate (LAL) gelation test (Wako Pure 
Chemical Industries Ltd., Japan). Gelatin with an isoelectric point of 9 (PI9) was 
kindly provided by Nitta Gelatin Co., Japan. 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC) and N-hydroxysuccinimide (NHS) were purchased from 
Nacalai Tesque, Japan. Mφ activating agents lipopolysaccharide (LPS; 
Escherichia coli serotype 055:B5) and recombinant murine IFN- were obtained 
from Sigma-Aldrich and Peprotech, respectively. Recombinant macrophage-
colony stimulating factor (M-CSF) was from Peprotech. Iscove’s Modified 
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Dulbecco’s Medium (IMDM) was purchased from Invitrogen, Japan. Heat-
inactivated fetal bovine serum (HI-FBS) was prepared by heating FBS 
(Hyclone™ Thermo Scientific Inc., Japan) at 56C for 30 min. Griess-Romijn 
Nitrite reagent was from Wako Pure Chemicals Ltd. The antibodies used were: 
mouse monoclonal anti-iNOS/NOS Type II (BD Biosciences), mouse 
monoclonal anti-β-actin (Sigma-Aldrich), rabbit polyclonal anti-NF-B p65 (clone 
Poly6226; BioLegend), horseradish peroxidase (HRP)-conjugated goat anti-
mouse IgG (Cell Signaling Technology, Japan) and Alexa Fluor 488-conjugated 
goat anti-rabbit IgG (Invitrogen). Hoechst 33342 was from Invitrogen. Other 
reagents used were all of reagent grade and used without further purification. 
 
2.2 Mouse bone marrow-derived mφ culture 
Mφ were isolated from 8-week old male Balb/c mice according to a 
protocol approved by Kyoto University Animal Care Committee. Briefly, bone 
marrow was flushed from femurs and tibias, washed once in IMDM containing 
2% HI-FBS, followed by removal of erythrocytes using BD Pharm Lyse buffer 
(BD Biosciences). Cells were then centrifuged at 2,300 g for 5 min at 4C, and 
resuspended in IMDM supplemented with 20% HI-FBS, 50 ng/ml of M-CSF, 2 
mM L-glutamine and 1% penicillin/streptomycin. Approximately 5 × 106 cells 
were plated in 10-cm bacteriological petri dishes and cultured at 37C in a 
humidified incubator in 95% air/5% CO2. The media was changed on day 4 and 
cells were harvested on day 7. At this stage, > 97% of adherent cells were pure 
mφ (both F4/80 and CD11b positive) as assessed by FACS analysis. These 




2.3 Preparation of GAG-immobilized surfaces 
Twenty-four well tissue culture plates (Corning Costar, Japan) were pre-
coated with 0.1% PI9 gelatin solution for 1 h at RT. For the covalent 
immobilization of GAGs to the gelatin layer, carboxylic acid groups of GAGs 
(100 µg/ml in MilliQ water) were pre-activated with a mixture of 2.5 mM EDC 
and 5 mM NHS for 15 min at RT. To each well was then added 250 µl of the 
activated GAG solution, and the plates were agitated gently for 2 h at RT 
followed by three washes with PBS. Using a DMMD assay for GAG 
quantification [27], it was determined that approximately 50-60% of the added 
GAGs was successfully immobilized onto the surface, with no further release of 
immobilized GAGs into the medium after 24 h incubation of the wells in IMDM at 
37C (results not shown).  
 
2.4 M1 mφ cultured with immobilized or soluble GAGs 
Mφ were detached by 10 min incubation with cold 5 mM EDTA-PBS 
followed by repeated pipetting. After centrifugation at 2,300 g for 5 min, 6  104 
cells were plated onto GAG-immobilized surfaces in IMDM with 0.1% bovine 
serum albumin (BSA; 500 µl/well). After 1 h incubation at 37°C, cells were 
elicited to pro-inflammatory (M1) phenotype by adding another 500 µl of IMDM 
with 2% HI-FBS containing activating agents IFN- plus LPS (IFN-/LPS) to a 
final concentration of 20 ng/ml and 100 ng/ml, respectively.  
To evaluate the modulatory effects of soluble GAGs on M1 mφ, cells were 
seeded into uncoated 24-well tissue culture plates for 1 h before exposure to 
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IFN-/LPS for an additional 24 h in the presence of GAGs (100 µg/ml). Culture 
supernatants were then collected, centrifuged at 2,300 g for 5 min at 4C to 
remove cellular debris, and stored at -30C until assayed. Cells seeded into 
standard tissue culture plates (i.e. without any coatings) and stimulated with or 
without activating agents were served as positive and non-stimulated (NT) 
controls, respectively.  
 
2.5 Griess assay for NO measurement 
Nitrite, a stable metabolite of NO, was measured in the culture 
supernatants using a Griess assay as described previously [30]. Briefly, 100 µl 
of culture supernatant was mixed on a 96-well plate with 100 µl of Griess-
Romijn Nitrite reagent (100 mg/ml in MilliQ water). After 10 min of incubation at 
RT, optical density (OD) at 540 nm was measured using a VersaMax™ 
microplate reader (Molecular Devices). The values were corrected for 
background levels of “no cell” blank that contains only GAGs. Preliminary 
studies indicate background interference by C6S and C4S occurs at the 
concentration  100 µg/ml, and so some samples were analyzed after diluted to 
50 µg/ml that reproducibly exhibits low background levels. The amount of nitrite 
in the culture supernatant was calculated using NaNO2 as a standard.  
 
2.6 Measurement of cytokine levels by ELISA 
IL-6, TNF-, IL-10 and TGF-1 levels in culture supernatants were 
assayed using commercial ELISA kits from R&D Systems followed the 




2.7 Western blot analysis 
Expression of iNOS, arginase I and -actin was quantified by western blot 
analysis. Briefly, 2.5  106 cells were seeded on 10-cm bacteriological dishes 
for 1 h, followed by activation with IFN-/LPS or LPS in the absence or presence 
of C6S. Cells were then dislodged with 5 mM EDTA/PBS, pelleted, 
resuspended in cold lysis buffer (0.1% Nonidet P-40, 1 mM EDTA, 150 mM 
NaCl and 50 mM Tris HCl, pH 7.4) with freshly added protease inhibitor 
(complete protease inhibitor cocktail tablets; Roche) and sonified (2 x 10 sec). 
The supernatant was collected after centrifugation at 10,000 g for 10 min and 
assayed for protein content by the BCA assay (Pierce, USA). After heat 
denaturation, aliquots containing 40 µg of protein were resolved on a 10% SDS-
PAGE gel at 20 mA constant current. Proteins were transferred to the 
polyvinylidene difluoride (PVDF) membrane using a BioRad mini trans-blot cell 
(30 V, 2 h). The membrane was blocked with 2.5% BSA in Tris-buffered saline 
(TBS; pH 7.5) containing 0.1% Tween 20 (TBST) for 1 hr at RT before overnight 
incubation at 4°C with mouse monoclonal anti-iNOS/NOS Type II or anti-β-actin 
antibodies (both were diluted 1:1000 in blocking buffer). After three 5-min 
washes in TBST, membranes were incubated with HRP-conjugated goat anti-
mouse IgG (1:5000 dilution in TBST) for 1 h. Following repeated washing, 
immunoreactivity was detected by incubating the membranes with 
SuperSignal West Pico chemiluminescent substrate (Pierce) for 5 min and 





2.8 Arginase activity assay 
Cells treated as described in Section 2.7 were lysed with 120 µl of 0.1% 
Triton-X 100 containing freshly added protease inhibitor for 30 min at 4C with 
gentle shaking, sonified (2  10 sec) and centrifuged at 10,000 g for 10 min. 
The protein content was determined by the BCA assay. Arginase activity was 
measured by determining levels of urea production as previously described with 
slight modification [31]. Briefly, arginase was activated by adding 50 µl 50 mM 
Tris-HCl (pH 7.5) with 10 mM MnCl2 to 50 µl of the cell lysate, followed by 
incubation at 56C for 10 min. Activated lysate was mixed with 100 µl of 0.5 M 
arginine solution (pH 9.7). After an incubation of 1 h at 37C the reaction was 
stopped with 400 µl of acid mixture (H3PO4/H2SO4/H2O at a volume ratio of 
1:3:7). The urea formed was measured at 540 nm after mixed with 40 µl of -
isonitrosopropiophenone (9% in absolute ethanol) followed by heating at 95°C 
for 30 min. A standard curve was prepared using urea of known concentrations 
(0-150 µg/ml). Arginase activity is defined as pmol of urea produced per mg 
protein per min. 
  
2.9 Immunofluorescence staining for NF-B nuclear translocation 
The effect of C6S on nuclear translocation of NF-B was evaluated by 
seeding 6  104 cells mφ for 1 h in 8-well Lab-Tek chamber slides (Thermo 
Scientific Inc., Japan), followed by activation with IFN-/LPS in the absence or 
presence of C6S (100 µg/ml). At 15 min and 60 min post-treatment, cells were 
12 
 
rinsed twice with PBS, fixed with 4% PFA (15 min, RT) and washed thrice with 
PBS. Cells were permeabilised with cold acetone for 10 min at -20C and 
blocked for 1 h at RT in TBS containing 2% BSA, 2% normal goat serum (NGS) 
and 0.2% Triton-X 100. Cells were then stained with rabbit anti-p65 NF-B 
antibody (1:200 dilution in TBS containing 2% BSA, 2% NGS and 0.05% Triton-
X 100) overnight at 4C. This was followed by incubation with Alexa Fluor 488 
goat anti-rabbit IgG (1:200 dilution in TBS containing 2% BSA and 0.05% 
Triton-X 100). After each staining, unbound antibodies were washed with TBST. 
To visualize the nuclei, cells were incubated with 1 µg/ml of Hoechst 33342 for 
5 min at RT. After rinsed thrice with TBS, the slides were mounted and 
examined with an Olympus AX80 fluorescence microscope. Negative controls 
with the omission of primary antibodies were used for background correction. In 
each experiment, a minimum of six fields (i.e.  200 cells) were examined and 
assessed. Nuclear translocation of NF-B is given as the ratio between the 
immunopositive nuclei over the total number of nuclei.  
 
2.10 Statistical analysis 
Results are presented as mean  standard deviation (SD) of at least three 
independent experiments. Statistical comparisons between groups were 
performed using Student’s t test or one-way analysis of variance (ANOVA) with 
Tukey post hoc test, as appropriate. For arginase assay, statistical significance 
was determined by the non-parametric Wilcoxon signed rank test. A p value < 
13 
 
0.05 was considered statistically significant. All statistical analyses were done 
using SPSS 17.0 software (SPSS Inc., Chicago, IL). 
 
3. Results 
3.1 Effects of immobilized and soluble GAGs on IFN-/LPS-induced NO 
production by mφ 
In the first set of experiments, mouse bone marrow-derived mφ were 
exposed simultaneously to IFN-/LPS and GAGs (either immobilized or soluble) 
for 24 h, before culture supernatants were assayed for nitrite accumulation as 
an indicator of NO production (Figure 1). As a positive control of M1 mφ 
activation, cells seeded into uncoated wells and stimulated with IFN-/LPS 
alone exhibited nearly 36-fold increment (7.1  0.9 µM) in NO levels compared 
to the NT control. Gelatin coating as a precursor layer for the covalent 
immobilization of GAGs had no significant effect on NO production in these cells 
(97.5  2.4% of the positive control values; p>0.05). As such, all results 
obtained were normalized arbitrarily to positive control, which was taken as 
100%. As shown in Figure 1, the enhancement of M1 mφ NO production was 
differentially modulated by immobilized GAGs, in which C4S, HA and HS 
resulted in small, but statistically significant reduction in NO production by M1 
mφ (p<0.05). Conversely, effects of GAGs on NO production appeared overall 
more pronounced when presented to activated cells as soluble molecules: (a) 
HS dramatically increased NO production by M1 mφ up to 151  22% (p<0.05); 
(b) NO levels remained unchanged in the presence of Hp or HA; and (c) both 
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C6S and C4S reduced NO production to 51  8% and 71 ± 9% (p<0.05), 
respectively (Figure 1).  
As an additional control, we also incubated mφ with individual GAG in the 
absence of activating agents for 24 h and measured NO levels in culture 
supernatants. The levels were negligible for all the GAGs, indicating that these 
molecules alone do not provoke inflammatory responses nor do they contain 
microbial contaminants (data not shown). 
 
3.2 Dose- and time-dependent suppression of mφ NO production by C6S  
 We next examined the dose-relationship between C6S, the most 
efficacious inhibitor determined above, and NO production by M1 mφ. As shown 
in Figure 2a, soluble C6S exerted a biphasic effect on NO production by cells, in 
which it suppressed its production in a dose-dependent manner from 10-100 
µg/ml, followed by a reversion to control values at higher concentrations. Of 
note, C6S did not affect mφ viability at the concentrations used, as examined by 
crystal violet assay (Appendix A). Therefore, any decreases in NO levels could 
not be attributed to cell death. 
 On the other hand, no significant changes in NO production were 
observed in M1 mφ cultured on C6S-immobilzed surfaces with a wide range of 
coating concentrations (Figure 2b), supporting our hypothesis that the mode of 
GAG presentation has a great impact on their immunomodulatory properties.  
 As part of these studies, we also evaluated the effects of C6S on NO 
production by LPS-activated mφ. As expected, LPS increased the NO release 
to a lesser extent than IFN-/LPS stimulation, resulting in 9-fold increment (1.8  
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0.5 µM). Likewise, a biphasic response was obtained when these cells were 
exposed to different C6S concentrations, with maximal inhibition (to 34.4  11% 
of control levels) also occurring at 100 µg/ml (Figure 2c). This dose was thus 
used for the subsequent experiments. 
 The time course of NO production by M1 or LPS-activated mφ in the 
absence or presence of C6S was also investigated (Figure 3). In positive 
controls, NO production was readily detected by 4 h post-stimulation and 
increased in a time-dependent manner. After 24 h, NO production by LPS-
activated mφ reached almost the plateau, but in M1 mφ NO release was still 
increased gradually in a time-dependent manner. In both cases, adding of C6S 
into the medium attenuated NO production by cells throughout the incubation 
period. Moreover, C6S caused a 14-h delay in the onset of NO production in 
LPS-activated mφ (Figure 3b). Nitrite levels in the NT control were negligible 
throughout the experimental period (data not shown).  
 
3.3 Effects of C6S treatment sequences on NO production     
 To examine the effects of pre- and post-treatment of C6S on mφ NO 
production, cells were either pre-treated with C6S for 24 h before an additional 
24-h exposure to IFN-/LPS or LPS, or vice versa (see Appendix B for detailed 
procedures). As shown in Figure 4, both regimens were effective in reducing 
NO levels in activated mφ, although different dose-response patterns were 
obtained. Interestingly, the reduction was more pronounced in the cells that had 
been pre-treated with C6S, with maximal inhibition (to 33-34% of control levels) 
was achieved with as low as 50 µg/ml of C6S (Figure 4a). When Figure 2 and 
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Figure 4 are compared, pre-treatment appears to be the most efficacious 
regimen among the three treatment sequences (i.e. co-, pre- and post-
treatment). 
 
3.4 Effects of C6S on cytokine production by activated mφ  
 Given the inhibitory effects of C6S on NO production in activated mφ, we 
asked whether production of major pro-inflammatory (IL-6 and TNF-) and anti-
inflammatory (IL-10 and TGF-1) cytokines might also be influenced. We first 
assessed the basal levels of these cytokines in NT and activated mφ (as 
negative and positive controls, respectively). The NT control constitutively 
releases low levels of IL-6 and IL-10 (< 12 pg/ml), and relatively higher levels of 
TNF- and TGF-1 (198  15 pg/ml and 282  26 pg/ml, respectively) (Figure 
5a). Stimulation of these cells with IFN-/LPS or LPS for 24 h elicited robust 
increases (5-22 folds) in all cytokines except for TGF-1, with the highest 
increment was seen in the IL-6 level. Figure 5b shows that the presence of C6S 
even at low dose (25 µg/ml) was sufficient to reduce IL-6 levels in both activated 
m, with the maximal inhibition was obtained at 100 µg/ml of C6S for M1 mφ. 
The same dose of C6S also significantly suppressed the production of TNF- 
while enhancing the production of IL-10 in activated cells (p<0.05) (Figure 5c). 
TGF-1 levels in these cells were unaffected by C6S. 
 To elucidate the beneficial effects of C6S pre-treatment, we additionally 
examined the cytokine levels in these samples. Similarly to what we observed in 
NO production (Figure 4a), C6S pre-treatment exerts greater inhibitory effects 
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on IL-6 and TNF-α production by activated mφ than co-treatment (Figure 5d). 
Furthermore, a relatively higher level of IL-10 was noted in M1 mφ that pre-
treated with C6S (Figure 5d).  
  
3.5 Effect of C6S on mφ iNOS and arginase expression  
 To investigate the way in which C6S inhibits NO production, mφ activated 
for 24 h in the absence or presence of C6S were analyzed for their iNOS level 
using western blot. As shown in Figure 6a, C6S did not exert significant effects 
on IFN-/LPS-mediated induction of iNOS protein. In LPS-activated cells, 
however, addition of C6S led to 0.2-0.6 fold decreases in iNOS levels (p<0.05).  
 We next examined the influence of C6S on mφ arginase, an enzyme that 
metabolizes the substrate (L-arginine) of iNOS. Compared with the NT control, 
IFN-/LPS significantly reduced mφ arginase activity up to 59%, and this effect 
was abolished in the presence of C6S (Figure 6b). On the other hand, LPS 
significantly increased arginase activity in mφ. In these cells, addition of C6S 
only intermittently (~45% of experiments performed) augmented arginase 
activity (Figure 6b). 
 
3.6 Effect of C6S on nuclear translocation of NF-B in mφ 
In a final attempt to determine the mechanism of action of C6S, we 
evaluated its ability to inhibit NF-B activation. Cells were stimulated for 15 min 
or 60 min with IFN-/LPS in the absence or presence of C6S, and then 
examined for nuclear translocation of NF-B using an antibody against p65 
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subunit. As seen in Figure 7a and 7b, NT controls exhibit low constitutive 
nuclear translocation of NF-B (i.e. less than 15% of cells). A rapid and robust 
activation of NF-B was seen in 79  10% of cells within 15 min of IFN-/LPS 
stimulation, while after 60 min the value was gradually declined to 54  10% 
(Figure 7b).  Over the duration of stimulation, NF-B activation was significantly 
inhibited by 50-60% with the addition of C6S (Figure 7b).  
 
4. Discussions 
 Successful resolution of inflammation requires the shutting down of pro-
inflammatory mediator production by mφ. In the present study, 
immunomodulatory effects of immobilized and soluble GAGs (C6S, C4S, HA, 
Hp and HS) on murine mφ were compared by measuring NO. NO is produced 
primarily by mφ as a cytotoxic effector against pathogens, but can adversely 
influence the process by causing collateral tissue damage at high doses [32]. 
We demonstrate here that all GAGs studied except for Hp were able to 
modulate IFN-/LPS-induced NO release by mφ to varying extents, highlighting 
the importance of microenvironmental cues for mφ functions. In particular, the 
modulatory activities of soluble C6S, HA and HS altered markedly after 
immobilization, with the most striking change was seen in HS (Figure 1). In 
soluble forms HS enhances inflammatory responses in mφ, as shown here and 
also by others [24, 33, 34]. Conversely, immobilized HS significantly decreased 
the NO production by activated mφ. These results support our hypothesis that 
mode of GAG presentation may influence their immunomodulatory properties.     
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Overall, the modulatory actions of soluble GAGs on mφ are more 
apparent than the immobilized molecules. One possible explanation to this is 
consistent with the normal mode of existence of GAGs in vivo. Most GAGs exist 
naturally as covalent complexes with core proteins to form proteoglycans [12]. 
In this form, the molecules (binding sites) may not accessible to inflammatory 
cells including mφ. After injury, GAGs are degraded and released as soluble 
molecules, resulting in structural modifications and the unmasking of their 
functional binding sites [15, 35, 36]. In such settings soluble GAGs act as a 
molecular signal that allows rapid recognition of injury by the host defense 
system. These molecules also actively participate in the ensuing inflammatory 
process through specific signaling events [14, 15, 36], albeit the mechanisms 
and cellular consequences of these signals are only partially understood.  
GAGs display high degrees of heterogeneity with regards to degree and 
pattern of sulfation, molecular size and disaccharide composition [12]. The 
influence of these factors on GAG bioactivity has been studied extensively [37-
39]. According to our knowledge, no other investigations have so far reported 
on the impact of mode of GAG presentation on mφ functions. It is important to 
point out, though, that the dose of soluble GAGs (100 µg/well) selected in this 
study does not equivalent to the amount of surface-immobilized GAGs, which is 
estimated to be 6-8 µg/cm2 (i.e. 12.5 – 15.0 µg/well) using a DMMB assay 
(unpublished data). Further investigations on dose response of individual GAGs 
are thus required to verify their immunomodulatory activities. Although the 
results presented here are preliminary, we believe the findings provide useful 
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insights for the design of effective immunomodulatory therapies for 
inflammation-associated diseases. 
The anti-inflammatory activities of CS have been documented in in vitro 
studies with articular cells [23, 25] and in animal models of osteoarthritis [40]. 
The effects of CS, particularly C6S, on mφ functions are nevertheless less well 
characterized. Here we show that soluble C6S exhibited the strongest NO 
inhibitory activity among the GAGs tested, while surface-immobilized C6S 
exerted no effect (Figure 1 and Figure 2). In the present work, C6S was 
covalently conjugated onto the surface using carbodiimide chemistry. Given this 
method involves reactions through side carboxylic acid groups of C6S, it could 
block site-specific binding and reduces its bioactivity like those observed here. 
To address this issue, Wang et al. [41] developed a biomimetic attachment 
system that allows GAGs to be tethered via their chain ends. Interestingly, they 
found that the CS-immobilized surface enhanced NO production by RAW 264.7 
murine mφ. This observation, together with our findings, suggests that surface-
immobilized CS shows no beneficial effects on the regulation of NO production 
by activated mφ.  
Apart from inhibiting NO production by activated mφ, C6S in solution also 
significantly reduced pro-inflammatory cytokines IL-6 and TNF- production by 
IFN-/LPS- or LPS-activated mφ (Figures 5b and 5c). In addition, we observed 
an opposite effect of C6S on CpG (a TLR9 ligand)-induced IL-6 production 
(unpublished data). These results appear to be somewhat contrast to an earlier 
report by Jin et al. [42], who showed that C6S suppressed IL-6 secretion 
induced by CpG, but not by LPS, in mφ-like J774.1 cells. We speculate that the 
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differential effects of C6S on pro-inflammatory mediator production are 
dependent on mφ populations, which were shown differ in their cytokine 
production after LPS stimulation [43]. TNF- is a pivotal cytokine in the 
pathogenesis of inflammation, where it can induce the production of other 
cytokines including IL-6 [44-46]. Antibody blockade of TNF- is currently FDA-
approved for the treatment of Crohn’s disease [47] and rheumatoid arthritis [48], 
and has been successful in alleviating inflammation. On the other hand, IL-6 is 
an useful biomarker of numerous inflammation-associated diseases including 
psoriasis [49], osteoarthritis [50, 51], atherosclerosis [52] and diabetes [53] etc. 
In a broader context, the inhibitory effects of C6S on both TNF- and IL-6 could 
have profound implications for the treatments of these diseases.   
Specifically, our data indicates that the C6S-mediated suppression of mφ 
pro-inflammatory phenotype was also possibly accompanied by changes 
towards anti-inflammatory/wound healing M2 phenotypes, as evidenced by an 
increase in the IL-10 level (Figures 5c and 5d). One of the known functions of 
IL-10 is its ability to inhibit the generation of NO and pro-inflammatory mediators, 
including TNF-α, IL-6 and IL-1 by IFN-/LPS- or LPS-activated mφ [54, 55]. 
Numerous animal studies also indicate that IL-10 plays essential roles in 
attenuating excessive inflammatory responses and in promoting wound healing 
[56-58]. Intriguingly, the basal levels of another anti-inflammatory cytokine TGF-
1 were unaffected by both activating agent stimulation and C6S at 24 h post-
treatment (Figure 5). As cytokine production by activated mφ is time-dependent 
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[59], additional studies (e.g. time-course of TGF-1 induction) are thus required 
to elucidate this issue. 
The anti-inflammatory effects of C6S as shown in the present work was 
due to its interactions with mφ, rather than a direct binding of C6S with 
activating agents or pro-inflammatory mediators that impedes their detection in 
the supernatants. This idea is supported by our results showing that (a) in the 
absence of C6S, the release of NO from activated mφ reached almost a plateau 
between 24 and 48 h post-stimulation, and the same trend was seen even in 
the presence of C6S (Figure 3); (b) in co-treatment, the presence of excess 
amount of C6S compared to activating agents (i.e. 100 µg/ml versus 20 ng/ml of 
IFN- and 100 ng/ml of LPS) did not completely block their pro-inflammatory 
effects; and (c) in the case of pre-treatment where C6S was omitted from media 
for mφ activation, reduction of inflammatory mediator production could still be 
observed (Figure 4a and Figure 5d). This hypothesis is also in some way 
supported by the finding that C4S molecules do not form complex with CpG as 
examined by size-exclusion chromatography [60]. 
Current knowledge about the mechanisms that regulate NO synthesis in 
mφ essentially concerns iNOS and arginase [8, 61]. Our investigation indicates 
that C6S was able to exert some effects on iNOS protein levels and arginase 
activity in LPS-activated and M1 mφ, respectively (Figure 5), but the magnitude 
of their changes is insufficient to explain the observed anti-inflammatory actions 
of C6S. In contrast, nuclear translocation of NF-B, a key transcriptional 
regulator in inflammation, was profoundly suppressed by C6S throughout the 
experimental period (Figure 7), suggesting the possibility that NF-κB pathway is 
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a mechanism through which C6S inhibits the production of NO, IL-6 and TNF-. 
In support of our observation, the inhibitory effects of CS on NF-B activation 
have been described by other investigators for chondrocytes [22, 62], 
synoviocytes [23] and T cells [63]. Nonetheless, the mechanisms by which C6S 
inhibits NF--B activation remains unclear and requires further investigation. 
There are at least two ways in which C6S can act on NF-B nuclear 
translocation: (a) a negative signal may be delivered by C6S following an 
interaction with their specific receptors on mφ; (b) C6S may act as an 
antagonist, which interferes with the binding of LPS to membrane receptors (e.g. 
TLR4) on mφ. Consistent with the latter hypothesis, it was demonstrated that 
C6S was able to interact with the TLR4 receptor complex in LPS-stimulated 
chondrocytes [62]. Experiments are currently underway to further investigate 
our hypotheses. 
 Lastly, to mimic a more clinically relevant scenario, mφ were exposed to 
C6S at the same time as activating agents in most of our experiments. We 
additionally examined whether or not C6S was able to inhibit mφ NO and 
cytokine production if administered at different times relative to activating agent 
challenge. We found that all three treatment sequences were effective in 
reducing NO levels in activated mφ, with the highest magnitude of the inhibitory 
effects was obtained with pre-treatment (Figure 2 and Figure 4a). We thus 
speculate that, in addition to its anti-inflammatory effects, C6S may also serve 
as a potential protective agent against microbial (LPS-induced) infection. 
Moreover, C6S administered after mφ had polarized to M1 phenotypes (i.e. in 
the case of post-treatment) was still able to manipulate their NO production 
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(Figure 4b), revealing remarkable plasticity of mφ, as documented previously by 
Stout et al. [64].  
 
5. Conclusion 
This study presents the first evidence demonstrating that immobilization of 
certain GAGs (C6S, HA and HS) alters their immunomodulatory activities, such 
that they affect IFN-/LPS-induced NO production by murine mφ in ways distinct 
from soluble GAGs. The data presented here provide further evidence to 
support the anti-inflammatory and protective roles of soluble C6S. In particular, 
the C6S-mediated suppression of mφ pro-inflammatory phenotype, possibly 
accompanied by changes towards anti-inflammatory/wound healing M2 state, 
offers significant potential for the treatment of inflammatory diseases. The 
effects of C6S on activated mφ may be ascribed at least in part to suppression 
of NF-B nuclear translocation. Experiments are underway to further dissect the 
anti-inflammatory actions of C6S. 
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Figure 1.   Effects of mode of GAG presentation on IFN-/LPS-induced NO 
production by mφ. Mouse bone marrow-derived mφ were stimulated with IFN-
/LPS in the presence of either immobilized or soluble GAGs for 24 h, before 
culture supernatants were assayed for nitrite accumulation as an indicator of 
NO production (see Materials and Methods for details). Results were 
normalized and presented as percentage of positive control.  p<0.05 versus 
positive control; * p<0.05; n = 3-5 from three independent experiments. 
 
Figure 2.   Effects of C6S concentration on NO production by activated mφ. Mφ 
were stimulated with IFN-/LPS for 24 h (a) in the presence of varying 
concentrations of soluble C6S, or (b) after plated on the C6S-immobilized 
surfaces (note: the x-axis represents the concentration of C6S coating solution). 
(c) NO production by LPS-activated mφ in relation to soluble C6S concentration. 
Nitrite levels in supernatants were measured using a Griess assay as detailed 
in Materials and Methods. * p<0.05;  p<0.05 versus all other groups; § p<0.05 
versus all other groups except 100 µg/ml; # p<0.05 versus all other groups 
except 50 µg/ml; n = 6 from three independent experiments. 







Figure 3. Kinetics of NO production by activated mφ in the absence or presence 
of C6S. Cells seeded into uncoated 24-well tissue culture plates were activated 
with (a) IFN-/LPS (M1) or (b) LPS in the absence (,) or presence (,) of 
100 µg/ml C6S for 48 h to analysis the accumulation of nitrite in culture 
supernatants at various time intervals. Shown here are representative plots 
from three independent experiments performed in duplicate. 
 
Figure 4. Effects of C6S treatment sequences on NO production by activated 
mφ. IFN-/LPS (M1)- or LPS-activated mφ were (a) pre-treated or (b) post-
treated for 24 h with the indicated concentrations of C6S as detailed in 
Appendix B, after which NO levels in culture supernatants were measured. * 
p<0.05 versus 0 µg/ml; n = 9 from three independent experiments. 
 
Figure 5. Cytokine production by mouse bone marrow-derived mφ. (a) Cytokine 
levels in the NT control and mφ activated with IFN-/LPS (M1) or LPS alone for 
24 h. (b) Dose-response effects of C6S on IL-6 production by activated mφ. 
Cells were stimulated with IFN-/LPS (M1) or LPS in the presence of varying 
C6S concentrations for 24 h, after which the supernatants were subjected to 
ELISA for IL-6. Changes of other cytokine secretion by activated mφ in 
response to (c) co-treatment or (d) pre-treatment of 100 µg/ml of C6S. p<0.05 
versus NT control; * p<0.05 versus corresponding control; ** p<0.01 versus 




Figure 6. Effects of C6S on iNOS and arginase activity in activated mφ. Mφ 
were stimulated for 24 h with IFN-/LPS (M1) or LPS in the absence or 
presence of 100 µg/ml of C6S. Total cell lysates were then subjected to (a) 
western blot and density analysis for iNOS expression with β-actin serves as a 
loading control (n=4), or (b) arginase activity assay (n=6), as described in 
Materials and Methods. Dotted line indicates arginase activity in NT controls 
that was set at 100%. Horizontal bars denote medians. * p < 0.05; § p < 0.05 
(Wilcoxon signed rank test).  
 
Figure 7. Effects of C6S on NF-B nuclear translocation in activated mφ. (a) 
Representative immunofluorescence images showing nuclear localization of 
NF-B p65 (green) in mφ at 15 min after IFN-/LPS (M1) stimulation in the 
absence or presence of C6S. Hoechst 33342 (blue) was used as a nuclear 
counterstain. Non-stimulated cells (NT) serve as experimental controls. No 
nuclear NF-B p65 staining was noted in the negative control with the primary 
antibody omitted (results not shown). (b) Quantitative analysis was performed 
by counting the percentage of cells with immunopositive nuclei.  p<0.05 versus 










Appendix A: Assessment of mφ viability using the crystal violet assay 
Mouse bone marrow-derived m were seeded onto uncoated 24-well tissue 
culture plates at 6  104 cells/well in IMDM with 0.1% BSA. After 1 h at 37°C, 
cells were incubated with 0-500 µg/ml of C6S for additional 24 h, after which the 
cells were washed twice with PBS, fixed with 4% PFA (15 min, RT) and stained 
with 0.1% crystal violet solution in 200 mM MES buffer (pH 6) for 15 min. After 
washing twice with PBS, 220 µl of 10% glacial acetic acid solution was added to 
each well to extract the dye. OD at 590 nm was then determined using a 
VersaMax™ microplate reader (Molecular Devices). The results indicated that 
C6S has no significant effects on mφ viability at the concentrations used 
(p>0.05; ANOVA test). Similar findings, not reported here, were obtained in the 
IFN-/LPS (M1)- or LPS-activated mφ. 
 
Appendix B: Scheme for C6S pre- and post-treatments 
Mouse bone marrow-derived m were seeded onto uncoated 24-well tissue 
culture plates at 6  104 cells/well in IMDM with 0.1% BSA, and incubated for 1 
h at 37°C. C6S (100 µg/ml in IMDM with 0.1% HI-FBS) was then added at 
different times relative to activating agent (i.e. IFN-/LPS or LPS) challenges as 
outlined above. Accumulation of nitrite in culture supernatants, an indicator of 
NO production by cells, was measured using the Griess assay as described in 
Section 2.5. 
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